secwatch.observer — SEC 8-K summary
======================================

Issuer:     EKSO BIONICS HOLDINGS, INC. (CHRN)
CIK:        0001549084
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0001549084-23-000018
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ekso Bionics Q1 revenues hit record $4.1M, up 61% YoY; net loss narrows to $4.4M
--------------------------------------------------------------------------------

- Revenue of $4.1M, a 61% increase from $2.6M in Q1 2022; gross margin improved to 49% from 47%.
- Net loss of $4.4M ($0.33 per share) vs. $4.6M ($0.36 per share) in Q1 2022.
- Booked 23 EksoHealth devices in Q1; cash position $16.3M at March 31, 2023.
- Sales & marketing spend rose to $2.1M from $1.6M, reflecting HMC acquisition costs.
- CEO cites multi-unit orders with large network operators and Indego product line contributions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549084/000154908423000018/0001549084-23-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549084/000154908423000018/ekso-20230427.htm
  HTML page:      https://secwatch.observer/filing/0001549084-23-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer